PCSK9 outcome trials: The results put into perspective of other clinical developments

10' education - Mar. 19, 2017 - Prof. Peter Sever - London, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 Expert Opinions Prof. Peter Sever describes the results of the FOURIER with respect to safety and efficacy. He puts the data into perspective of other trials and molecules.

Video navigation menu

Is it safe to go down that low and is there additional benefit from this LDL-c lowering? 00:53
Would we have expected more, given the magnitude of LDL-c reduction? 01:43
Who is eligible for these drugs? 02:20
How to put the results of FOURIER into perspective of other trials and molecules? 03:47
Insights on the effect on neurocognition in the EBBINGHAUS substudy 05:58

Educational information

This educational video is part of a series of PCSK9 Expert Opinions that are aimed to provide different perspectives and opinions from international experts in this field and may provide support with the interpretation and translation of new findings towards implications for clinical practice

The educational content reflects the personal opinion of the experts and is recorded as an independent educational service by PACE-CME

Disclosures

Prof. Peter Sever - National Heart & Lung Institute, Imperial College London, United Kingdom

Funding

Funding was provided by an unrestricted educational grant from Amgen

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.